Moxifloxacin Krka (Moxifloxacin)

Moxifloxacin is a broad‑spectrum antibacterial indicated for several respiratory and skin infections.

• Community‑acquired bacterial pneumonia: effective treatment of infection caused by susceptible organisms in adults.
• Acute bacterial sinusitis: resolves sinus inflammation due to susceptible bacteria.
• Acute bacterial exacerbation of chronic bronchitis: shortens duration and severity of bacterial flare‑ups.
• Skin and skin structure infections: eradicates susceptible pathogens in cellulitis, abscesses and wound infections.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death. This dual inhibition provides activity against both Gram‑positive and Gram‑negative organisms, including atypical respiratory pathogens.

Moxifloxacin may cause a range of adverse reactions, most of which are dose‑independent and related to its fluoroquinolone class.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional sense of light‑headedness.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, often linked to sudden activity.
• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe hypersensitivity: including anaphylaxis or Stevens‑Johnson syndrome.
• Central nervous system effects: seizures or psychosis in susceptible individuals.

Before prescribing Moxifloxacin, clinicians should assess patient‑specific risk factors and monitor for known safety concerns.

• Renal impairment: adjust therapy if significant kidney dysfunction is present.
• Hepatic disease: use with caution in patients with liver dysfunction.
• Cardiac risk: avoid in patients with known QT prolongation or concurrent QT‑prolonging drugs.
• Tendon disorders: advise patients to report tendon pain or swelling promptly.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Moxifloxacin can alter the plasma concentrations of several co‑administered medicines, requiring careful review of the patient’s medication list.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin.
• NSAIDs (e.g., ibuprofen, naproxen): increase risk of central nervous system stimulation and seizures.
• QT‑prolonging agents (e.g., quinidine, sotalol): may cause additive cardiac conduction delays.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Theophylline: potential increase in serum theophylline levels, watch for toxicity.
• Corticosteroids: may raise the risk of tendon rupture, advise caution.